Medicare’s Hospital Value-Based Purchasing program has not accelerated the improvement of patient experience beyond previous trends, according to a study reported this week in Health Affairs. “Instead, we found that the rate of improvements in patient experience has slowed since the program was implemented,” the authors said. “Over the entire study period, certain subsets of hospitals (such as small ones) seemed to have improved in patient experience more than other subsets (such as larger hospitals), yet even for the institutions that had greater improvement, the majority of the change occurred before implementation of the VBP program.” The study examined trends in multiple measures of patient satisfaction between 2008 and 2014. The Centers for Medicare & Medicaid Services began publicly reporting on patient-reported experience through the Hospital Consumer Assessment of Healthcare Providers and Systems survey in 2008, and tied Medicare payments directly to these measures through the VBP program in 2011. The authors said the study “adds to a growing body of literature suggesting that U.S. pay-for-performance schemes have had little to no effect on driving meaningful improvements in other patient outcomes.”

Headline
The Centers for Medicare & Medicaid Services announced that it will exercise enforcement discretion for inpatient rehabilitation facility admissions from…
Headline
The Centers for Medicare & Medicaid Services has released 2027 Medicare Advantage plan information, including star ratings, through the Medicare Plan…
Headline
The AHA provided comments to the Medicare Payment Advisory Commission Oct. 2 on a discussion from the commission’s September meeting on its examination of…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 25 that it will expand the Inpatient Rehabilitation Facility Review Choice Demonstration to…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 28 that it projects declines in average premiums for Medicare Advantage and Part D in 2027.…
Headline
The Food and Drug Administration released draft guidance Sept. 24 that includes recommendations on non-clinical testing, clinical data and labeling for…